[8] [9] This sympathetic activation may be mediated through central nervous system pathways, as GLP-1 receptors are present in the hypothalamus and brainstem regions that regulate cardiovascular function
Emerging opportunities lie in the combination therapies that integrate glucagon like peptide 1 analogs with other metabolic disease treatments, enhancing the therapeutic value for patients
Among these, inflammation, oxidative str1ss and endoplasmic reticulum stress, alteration of adipokine secretion pattern (particularly reduction in secretion of insulin-sensitizing adipokines such as adiponectin, omentin, and vaspin) and hormones, reduced catabolism of branched-chain amino acids, and release of exosomes carrying microRNAs capable of interfering with insulin signaling [20, 21]
What we eat has a significant impact on how our bodies respond, not just how much